Hypertension Clinical Trial
Official title:
Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial
Purpose of this study
1. Intensive education for low salt diet will be enhance the anti-proteinuric effect of
Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in
Koreans compared to conventional prescription of medication.
2. Intensive education for low salt diet will decrease the amount of 24 hour-urine sodium
excretion compared to control group, effectively.
1. Background
A. The chronic kidney disease (CKD) is the one of the main burden of chronic diseases
and the prevalence of CKD is increasing in worldwide. In Korea, the prevalence of CKD
was reported as 13.7% among urban Korean adults in 2008 by our study group.
B. It is well known the CKD is the most important risk factor to cardiovascular events,
cardiovascular mortality, all cause-mortality, and hospitalization. The cost of the
management for the CKD was high and it took 3.25% of all budgets for medical
reimbursement in 2004 for all Koreans, which was ranked on the top of expenditure for
single disease category.
C. The most popular risk factors to CKD progression are aging, obesity, hyperlipidemia,
diabetes mellitus, hypertension, and proteinuria. The hypertension and proteinuria also
cause the cardiovascular events and increase the mortality rate.
D. The inhibitors for renin-angiotensin aldosterone system, angiotensin II type I
receptor blocker (ARB) and angiotensin converting enzyme inhibitor (ACEI), are well
known medications to prevent cardiovascular events and renal functional deterioration
to end stage renal disease(ESRD) in patients with hypertension, non-diabetic CKD, or
diabetic nephropathy. One of the adverse events of ARB is the decrease of hemoglobin.
Inoue et al reported the level of hemoglobin was decreased in amount of 0.45 ±0.89 g/dL
after prescription of ARB and valsartan decreased the erythropoietin in 6 days after
medication. The exact mechanism of decrease of hemoglobin by ARB was not fully verified
but it is related to decrease effects of angiotensin II on aggravating hypoxia in the
kidney and on the activation of hypoxia-inducible factor 1α (HIF1a) and then decrease
the production of erythropoietin as in the report of Durmus et al. Considering that the
relationships between ARB usage and decrease of proteinuria in transplanted kidney,
between aggravation of hypoxia or HIF1a and CKD, and between ARB and the decrease of
HIF1a or erythropoietin(EPO), we could postulate that the decrease of hemoglobin would
not be a adverse effect of ARB to deteriorate patients' condition but a co-phenomenon
of ARB's anti-RAS effect and a marker of ARB's effectiveness.
E. The anti-proteinuric effect of ARB is decreased by high salt intake. For example,
ARB treatment without low salt intake decreased proteinuria by 30% in patients with
proteinuria 2-10g/day compared to baseline value and addition of low salt diet to ARB
treatment further decreased proteinuria up to 25%. But, using slow salt tablets,
increase of daily intake of sodium diminished the anti-proteinuric effect of ARB in
diabetic nephropathy.
F. The previous studies for the effect of ARB on proteinuria affected by sodium intake
took the methods of controlled diet by researcher or using slow salt tablet but these
method are not practical to adopt in real clinical practice.
G. The moderate and mild decrease of daily sodium intake which lower the daily
excretion of sodium by 55 mEq/day had an effect of decrease of proteinuria by 11% in
hypertensive patients.
H. The mean amount of sodium of Korean diets was reported as high as 208 mmol/day in
Intersalt study, which is more than 11 g of salt. The recent reports also showed the
trend of high salt-intake by Koreans.
2. Rationale So, It is worth to do this study because
- high salt intake is prevalent in Koreans,
- high salt diet diminishes the effect of ARB on proteinuria
- the methods used in previous studies were not suitable to apply to clinical
practice,
- and there were no study to reveal the decrease of hemoglobin would the marker for
the effect of ARB and not be a adverse event of ARB.
3. Objectives
1. Primary objective: The difference between amount of albuminuria after usage of
Olmesartan and amount of albuminuria after prescription of Olmesartan with
intensive diet education in intervention group is higher than the difference of
albuminuria in control group.
2. Secondary objective:
Item 1: In all patients, Olmesartan decreases the albuminuria. Item 2: In all patients,
the change of hemoglobin after prescription of Olmesartan is proportional to the change
of albuminuria and serum erythropoietin.
Item 3: Intensive education for low salt diet induces the significant decrease of daily
sodium excretion in Intervention group compared to control group.
Item 4: Intensive education for low salt diet induces the significant decrease of blood
pressure in Intervention group compared to control group.
4. Study Flow
- Period
1. Washout period (-8 weeks;Point 0 to 0 weeks; Point 1)
2. Olmesartan Period ( 0 week; point 1 to 8 weeks; point 2)
3. Intervention period (8 week ; point 2 to 16 weeks; point 3)
- For patients with taking ACEI, other ARB, diuretics, or renin inhibitor, already;
Initial wash-out period for 8 weeks, and then (point 1) prescription of Olmesartan
40 mg qd for 8 weeks, and then (point 2) allocation to Intensive group or control
group for 8 weeks, and then the study will be over (point 3).
- For patients without taking ACEI, other ARB, diuretics, or renin inhibitor; For
initial 8 weeks, adjust the blood pressures around 140/90 mmHg, and then (point 1)
prescription of Olmesartan 40 mg qd for 8 weeks, and then (point 2) allocation to
Intensive group or control group for 8 weeks, and then the study will be over
(point 3).
- Blood pressure control Adjust the blood pressures around 140/90 mmHg with other
hypertensive drugs except ACEI, other ARB, diuretics, or renin inhibitor during
whole period.
- Intensive diet education:
For 8 weeks, dietitian will call patients to take the information according to pre-defined
questionnaire, to check the daily diet habit and daily food taken, and to guide how to
lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |